Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsCreative Biolabs have established a platform to analyze amino acid sequence of therapeutic drug candidates, strictly following the ICH Topic Q6b guideline. The amino acid sequence of the desired product should be evaluated utilizing approaches such as amino acid composition, terminal amino acid sequence, peptide map, sulfhydryl group(s) and disulphide bridge analysis and then compared with the amino acid sequence deduced from the gene sequence of the desired product. Terminal amino acids should be analyzed to determine the nature and homogeneity of the amino (N-) and Carboxy (C-) terminal amino acids. When the desired product is found to be heterogeneous with the respect on amino acids, the relative proportion of variant forms should be identified using an appropriate analytical procedure. The terminal amino acids should also be compared with the ones deduced from the gene sequence of the desired protein.
Degradation products exist commonly together with the desired products. Degradation products are molecular variants, generated from alterations in the desired protein product or product-related substances over time and/or by the factors of, e.g., light, pH, temperature, water, or by reaction with an excipient and/or the immediate container/closure system. Such changes may be caused during processing and/or storage by oxidation, deamidation, aggregation, or proteolysis.
For the assessment of the N-termini of the desired product, Creative Biolabs utilize automated Edman Degradation (N-terminal sequencing) for divided light chains and heavy chains of desired antibodies. This procedure includes reduction and separation of light chains and heavy chains for independent sequencing (15 cycles). To provide an orthogonal confirmation of the N-termini (to the extent possible), mass spectrometry based sequencing via MSe and MS/MS (Q-TOF) will be performed. For the assessment of the C-termini of the product, Creative Biolabs combine data from intact molecular weight analysis (superlink) and peptide mapping (superlink) to identify and sequence the C-terminal peptides. All the proteins are characterized in house in 2-3 week.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
